Two Sigma Advisers’s Metacrine, Inc. Common Stock MTCR Stock Holding History

Two Sigma Advisers’s Portfolio MTCR Stock Details MTCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-44,200	Closed	-$19.8K	–	2837
2022 Q4	$19.8K	Sell	44,200 -18,300	-29%	-$7.57K	﹤0.01%	2429
2022 Q3	$30K	Sell	62,500 -25,400	-29%	-$12.5K	﹤0.01%	2418
2022 Q2	$44K	Sell	87,900 -1,000	-1%	-$484	﹤0.01%	2491
2022 Q1	$54K	Buy	88,900 +33,000	+59%	+$17.3K	﹤0.01%	2584
2021 Q4	$38K	Sell	55,900 -80,500	-59%	-$144K	﹤0.01%	2504
2021 Q3	$468K	Buy	136,400 +87,000	+176%	+$271K	﹤0.01%	1951
2021 Q2	$188K	Buy	49,400 +38,500	+353%	+$159K	﹤0.01%	2280
2021 Q1	$68K	Sell	10,900 -5,900	-35%	-$52.3K	﹤0.01%	2477
2020 Q4	$132K	Buy	+16,800	New	+$154K	﹤0.01%	2237

Other funds holding MTCR

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

Two Sigma Advisers's MTCR Position: Q1 2023 in Review

Two Sigma Advisers sold out of Metacrine, Inc. Common Stock (MTCR) in Q1 2023, closing a stake of 44,200 shares — an estimated $19.8K sold.

Two Sigma Advisers first reported a position in MTCR in Q4 2020 and held it in 9 quarters. The position peaked at $468K in Q3 2021. 5 funds tracked by Wall St. Rank hold MTCR as of Q1 2023.

Two Sigma Advisers reported no remaining Metacrine, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Two Sigma Advisers sold 44,200 Metacrine, Inc. Common Stock shares in Q1 2023, an estimated $19.8K.
Two Sigma Advisers first reported a position in Metacrine, Inc. Common Stock in Q4 2020 and held it in 9 quarters.
Two Sigma Advisers's Metacrine, Inc. Common Stock position peaked at $468K in Q3 2021.
5 funds tracked by Wall St. Rank held Metacrine, Inc. Common Stock as of Q1 2023.

Based on Two Sigma Advisers's 13F filing for Q1 2023, filed 15 May 2023.